All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for EISAI, INC. · human health care company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Oct 18, 2025

Official filing document

Bills named in this filing 4

S 2296
National Defense Authorization Act for Fiscal Year 2026
HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
S 891
Bipartisan Health Care Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act (S.2296/H.R.3838); PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21).

Budget/Appropriations

H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions.

Trade (domestic/foreign)

Issues related to supply chain and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.